Vitrolife AB (publ)
Vitrolife AB (publ)
Your view on VTRLY
Overview
What the company does, where it operates, and who runs it.
About Vitrolife AB (publ)
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Bronwyn Brophy O'Connor
- Headquarters
- Gustaf Werners gata 2, Gothenburg, SE
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Bronwyn Brophy O'Connor
- Headquarters
- Gustaf Werners gata 2, Gothenburg, SE
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products.
The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America.
The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Vitrolife AB (publ), and the rating behind it. VTRLY last traded at $9.50; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Vitrolife AB (publ). Starting points for Vitrolife AB (publ): EPS -$36.79, beta 2.06 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Vitrolife AB (publ). Vitrolife AB (publ) does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Vitrolife AB (publ). Trailing twelve-month EPS for Vitrolife AB (publ) stands at -$36.79. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Vitrolife AB (publ). Vitrolife AB (publ) has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Vitrolife AB (publ) valued side by side against its closest peers. Vitrolife AB (publ) is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Vitrolife AB (publ), and how their positions are changing. At a $1.29B market value, institutional positions materially move Vitrolife AB (publ)'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Vitrolife AB (publ) executives and directors. Shares of Vitrolife AB (publ) have traded between $9.50 and $18.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Vitrolife AB (publ). Vitrolife AB (publ) is a $1.29B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Vitrolife AB (publ). Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Vitrolife AB (publ). Coverage tracks Vitrolife AB (publ) within Medical - Devices (Healthcare). Press releases and market coverage, newest first.